logo

Lexicon Pharmaceuticals Inc. (LXRX)



Trade LXRX now with
  Date
  Headline
11/29/2018 9:13:03 AM Lexicon: FDA Advisory Committee To Review Investigational Sotagliflozin As Potential Treatment For Type 1 Diabetes
11/1/2018 7:23:35 AM Lexicon Pharma Q3 Net Loss $27.5 Mln Or $0.26/Shr Vs Loss Of $30.7 Mln Or $0.29/Shr Last Year
10/16/2018 8:10:45 AM Lexicon Pharma And Ipsen Biopharmaceuticals Canada Announce Health Canada Approval Of XERMELO
7/30/2018 7:10:01 AM Lexicon Pharma Q2 Net Loss $34.7 Mln Or $0.33/shr Vs. Net Loss $35.1 Mln Or $0.33/shr Last Year
6/23/2018 3:07:12 PM Lexicon Pharma Reports Positive 52-Week Results From Sotagliflozin In Tandem2 Study
6/18/2018 2:05:59 PM Wedbush Reiterates Lexicon Pharmaceuticals Inc. (LXRX) At Outperform With $42 Price Target
5/22/2018 4:33:28 PM Wedbush Reiterates Lexicon Pharmaceuticals Inc. (LXRX) At Outperform With $42 Up From $40 Price Target
5/22/2018 8:04:26 AM Sanofi Says FDA To Review Zynquista As Potential Treatment For Type 1 Diabetes
5/22/2018 8:01:47 AM Sanofi: FDA To Review Zynquista (sotagliflozin) As Potential Treatment For Type 1 Diabetes
5/7/2018 4:47:06 PM Wedbush Is Increasing Lexicon Pharmaceuticals Inc. (LXRX) FY18 Rev. Estimate To 80.4 M From 71.1 M
5/7/2018 4:46:43 PM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) FY19 Estimate To -0.72 From -0.69
5/7/2018 4:46:26 PM Wedbush Is Raising Lexicon Pharmaceuticals Inc. (LXRX) FY18 Estimate To -1.18 From -1.43
5/7/2018 4:46:09 PM Wedbush Is Increasing Lexicon Pharmaceuticals Inc. (LXRX) Q2 18 Estimate To -0.29 From -0.38
5/4/2018 8:05:21 AM Lexicon Reports Publication Of New XERMELO (Telotristat Ethyl) Data In Clinical Therapeutics
5/3/2018 7:20:38 AM Lexicon Pharma Q1 Net Loss $42.1 Mln Or $0.40/Shr Vs Loss Of $34.9 Mln Or $0.33/Shr Last Year
4/16/2018 7:40:49 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) 2018 Estimate To -1.43 From -1.22
4/16/2018 7:40:36 AM Wedbush Is Cutting Lexicon Pharmaceuticals Inc. (LXRX) 4Q18 Estimate To -0.31 From -0.27